Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FlexHD vs AlloDerm RTU in Breast Reconstruction
NCT03145337Unknown
- Sponsor
- MTF Biologics
- Start
- Jul 2017
- Primary completion
- Feb 2019
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by MTF Biologics. Primary endpoint: Post Reconstruction Complication Rates at 12 months. Status: unknown.
Beyond the preview
Go deeper on NCT03145337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03145337.